A Registry for Patients Taking Uptravi
Purpose
This is a US multi-center, prospective, real world, observational drug registry enrolling patients actively treated with Uptravi. Participating patients will be followed prospectively for a maximum of 18 months from the date of enrollment into the registry.
Condition
- Pulmonary Arterial Hypertension
Eligibility
- Eligible Ages
- Between 18 Years and 99 Years
- Eligible Genders
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- Signed patient informed consent form (ICF). - Patients ≥ 18 years of age at time of Uptravi initiation, and - Patients who initiate Uptravi: - at enrollment, or - less than or equal to 60 days prior to enrollment and have a documented titration regimen (defined as all documented dose changes including, but not limited to: starting dose and dates and highest tolerated dose and dates)
Exclusion Criteria
- Patients previously exposed to Uptravi treatment during a clinical trial. - Patients that previously discontinued Uptravi for any reason, prior to study enrollment (discontinuation defined as an interruption of therapy greater than or equal to 30 days). - Patients enrolled in a blinded clinical trial or in a clinical trial involving an unapproved drug.
Study Design
- Phase
- Study Type
- Observational [Patient Registry]
- Observational Model
- Other
- Time Perspective
- Prospective
Arm Groups
| Arm | Description | Assigned Intervention |
|---|---|---|
| Group/Cohort Information | This is a US multi-center, prospective, real world, observational drug registry enrolling patients actively treated with Uptravi. Participating patients will be followed prospectively for a maximum of 18 months from the date of enrollment into the registry. |
More Details
- Status
- Completed
- Sponsor
- Actelion